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From 1991 to 1998, Neisseria meningitidis serogroups A, B,
and C represented 2%-10% of strains isolated from cases of
bacterial meningitis in Yaoundé. During 1999 to 2000, the per-
centage of meningococci reached 17%, a proportion never
reported since recordkeeping began in 1984. The increase of
serogroup A meningococci and the emergence of W135 strains
highlight the need for increased surveillance for better diagno-
sis and prevention.
eisseria meningitidis serogroup A causes major epidem-
ics of meningitis in Africa, essentially within the African
meningitis belt  (1). Epidemics of cerebrospinal meningitis in
this belt are often enormous (1). During the first 9 months of
1996 in the World Health Organization (WHO) African
Region, 146,166 cases were reported to WHO; 15,783 were
fatal. During that year, 42,129 cases occurred in Burkina Faso,
7,244 in Mali, 16,050 in Niger, and 75,069 in Nigeria. These
four countries reported 95% of the cases in Africa in 1996, for
an overall case-fatality rate of 10.6% (2).
The recommended control practices in Africa involve vac-
cination with the meningococcal bivalent polysaccharide A/C
vaccine in response to epidemics. Efficient public health prac-
tice necessitates that epidemics be detected early, stocks of
vaccines be set up in target regions, and field vaccination with
the bivalent vaccine be rapid, since the quadrivalent
ACYW135 vaccine has limited worldwide supply and is more
expensive.
The presence of N. meningitidis serogroup W135 has been
confirmed in Africa for some time. In Burkina Faso in 1980,
1.3% of the meningococcal strains isolated from rhinopharyn-
geal carriers belonged to serogroup W135. In 1981 and 1982,
monitoring of the serogroups responsible for meningococcal
meningitis at Dakar (Senegal) and Niamey (Niger) showed
that 4% and 3% of strains, respectively, belonged to serogroup
W135 (3). In 1984 and 1985, 7% of N. meningitidis strains iso-
lated from meningitis cases in Gambia belonged to serogroup
W135 (4). In 1993 and 1994, two strains of N. meningitidis
W135 were isolated from patients in Mali; both belonged to
the ET-37 complex (5). More recently, in 1994, six strains of
serogroup W135 isolated from clinical cases in Gambia were
studied; they also belonged to the ET-37 complex. DNA mac-
rorestriction analysis of these strains identified four different
profiles in pulsed-field gel electrophoresis (PFGE), indicating
that the strains involved were closely related but different (6).
W135 strains are often isolated after intensive campaigns of
vaccination against meningococci of serogroups A and C
(3,4,6).
In spring 2000, an epidemic of N. meningitidis W135
infection broke out among Hajj pilgrims (for whom vaccina-
tion against meningococci of serogroups A and C is manda-
tory) and their close contacts. In all, 241 cases were reported in
Saudi Arabia and 90 in 13 other countries (7), including the
United States (4 cases) (8), the United Kingdom (33 cases),
and France (19 cases). All these strains showed markers of the
ET-37 complex; had an antigenic formula W135:2a:P1-5,2; a
sequence type ST-11; and the same profile on PFGE (9), con-
firming the clonal origin of the epidemic. Four W135 strains
isolated in U.S. patients epidemiologically linked to Hajj pil-
grims were further studied. The sequence of the porA gene
showed that these four strains had variable regions VR1 and
VR2 identical to those of the prototype P1.5,2 strain (8).
Apparently, the W135 strains isolated in Africa until 1995
did not cause large epidemics, even if isolated in the countries
in the African meningitis belt in which epidemics due to sero-
groups A meningococci are frequent (e.g., Niger, Mali, Sene-
gal, and Gambia). In Niger in 1981, only one W135 strain of
231 meningococci was isolated from a meningitis case (3).
Similarly, W135 accounted for 7 of 42 strains in 1982 in Niger,
and 3 of 76 strains in Senegal in 1981 to 1982 (3), 3 of 41 in
Guinea in 1984 to 1985 (4), and 2 of 75 strains isolated in
1991 to 1994 in six countries in the African meningitis belt
(5). However, available information shows that the case-fatal-
ity rate due to W135 strains was relatively high in Africa
before 1995, as in Europe during the recent Hajj 2000 epi-
demic: 6 (35%) of 17 cases in Africa before 1995 (in Senegal,
Gambia, and Niger) and 10 (18%) of 56 cases in Europe in
2000 (in the United Kingdom, France, and the Netherlands).
The Study
We report here a sudden increase in the number of menin-
gococcal strains isolated from cerebrospinal fluid (CSF) sent
to the Medical Biology Laboratory of the Pasteur Centre of
Cameroon (CPC) at Yaoundé in the 1-year period 1999 to
2000 (note that in Cameroon the administrative year begins on
July 1). Yaoundé, the capital of Cameroon, is a city of approx-
imately 1,500,000 inhabitants. Located in the forest zone at an
altitude of 750 m, about 400 km south of the southern limit of
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the African meningitis belt, it has a humid, tropical climate.
The CPC laboratory receives samples from patients admitted
to the principal hospitals of Yaounde and, in 1999 to 2000,
91.5% of CSF samples sent to the laboratory were from chil-
dren <15 years old; 81% were from children <5 years.
From 1984 to 1990, bacteria were isolated from 767
(5.8%) of 13,134 CSF samples; 42 (5.5%) of these were N.
meningitidis. This proportion was significantly lower than dur-
ing the 1991 to 2000 period (8.7%; p<0.05). We do not know if
there were changes in the population of patients using the CPC
services that might account for the slow increase in cases of
meningococcal disease. Slow improvement of laboratory prac-
tices and medical competence might account for slowly
increasing proportions of N. meningitidis over a 20-year
period. However, no major changes in laboratory techniques
occurred in 1999 at CPC that could account for the sudden
increase observed in 1999 and 2000. Moreover, during that 20-
year period, most CSF samples came from the same pediatric
wards of the neighboring Central Hospital of Yaoundé and
other major children’s hospitals.
The table shows the changes in isolation rates of N. menin-
gitidis from clinical cases at Yaoundé during 1991-92 to 2000-
01.  The number of meningococcal strains isolated has
remained small for the last 10 years, as would be expected in a
zone located at a considerable distance south of the African
meningitis belt and one in which pneumococci and Haemophi-
lus influenzae are the two most frequent bacterial agents of
meningitis. Most meningococcal strains isolated were sero-
group A, the most frequent group in Africa. The proportion of
meningococci identified in cases of bacterial meningitis varied
significantly in this period (p<0.01).
In the 2-year period 1998 to 2000, two events occurred.
The first was an increase in the number of isolates of N. men-
ingitidis; such isolates accounted for >19% of strains isolated
from cases of bacterial meningitis in 1999 to 2000, and 21% in
2000 to 2001—two to three times more than normal. We
checked records back to 1984 and found that in none of the
years in this period was such a large number of meningococci
isolated at Yaoundé. The second noteworthy event was the
appearance of serogroup W135 strains, which accounted for 9
(19%) of 48 meningococcal strains isolated in 1998 to 2000
versus 0 of 46 in 1991 to 1997 (p<0.01).
One W135 case occurred in January 1999 in a 12-year-old
boy from Yaoundé who had no known contact with a Hajj pil-
grim and no recent history of travel. On the four W135
patients from 1999 to 2000, one was male and three were
female. Ages were 2, 3, 29, and 37 years. Onsets of disease
were in July 1999 and in May and June 2000, i.e., after the
usual meningococcal peak in the dry season, and none had
known direct or indirect contact with each other or with a Hajj
pilgrim. In 2000 to 2001, four cases occurred, all in males
(aged 9, 15, 23, and 40 years); onsets of diseases occurred in
January 2001, then in March, May, and June. One of them was
in a 23-year-old student, who had been studying in Dakar
(Senegal) for 2 years; he became ill while observing holy days
in Cameroon. He could have been in indirect contact with Hajj
pilgrims, since he was Muslim and Senegal is largely Muslim.
Vaccination status was obtained for five of these nine patients:
two were vaccinated against meningococcal meningitis,
including the student.
The five strains of N. meningitidis W135 isolated in 1999
to 2000 were serotyped, subtyped, and studied by molecular
biology techniques. All belonged to the ET-37 complex and
had the antigenic formula W135:2a:P1.2,5. Two strains were
subjected to multilocus sequence typing; both were of
sequence type ST-11, typical of isolates of the ET-37 complex
(10). These five strains were indistinguishable by multilocus
DNA fingerprinting and showed markers of E-37 complex
(11). Finally, SpeI restriction profiles were determined by
PFGE: four of the strains were indistinguishable, and the final
strain differed by one band only. All these clones differed
slightly (by two bands for four isolates and by three bands for
Table. Isolation of Neisseria meningitidis from meningitis cases at Yaoundé, Cameroon, 1991–2001
Year No. of CSF samples
No. (%) of cases of bacterial 
meningitis
No. (%) of cases of 
meningococcal meningitis
No. of strains of each 
serogroup
1991-1992 1,246 131 (10.5)   8 (6.1) 6 A; 2 C
1992-1993 1,049 105 (10) 11 (10.5) 11 A
1993-1994 961   88 (9.2)   9 (10.2) 8 A; 1 B
1994-1995 722   69 (9.6)   6 (8.7) 2 A; 4B
1995-1996 998   70 (7)   4 (5.7) 1A; 1B; 1C; 1NT
1996-1997 1,255   97 (7.7)   2 (2.1) 2C
1997-1998 1,282   92 (7.2)   6 (6.5) 4A; 1C; 1NT
1998-1999 1,505 116 (7.7)   8 (6.9) 6A; 1B; 1W135
1999-2000 1,812 120 (6.6) 23 (19.2) 17A; 2B; 4W135
2000-2001 1,612 81 (5) 17 (21) 13A; 4W135
Total 1,2442 969 (7.8) 94 (9.7) 68A; 9B; 6C;9W135; 2NT
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one isolate) from the clone isolated from the Hajj pilgrims in
2000.
Conclusions
These results show an increase of serogroup A meningo-
cocci in Yaoundé and demonstrate the presence and circulation
of at least one indigenous clone of N. meningitidis W135 of
the ET-37 complex in Central Africa. The clone is very similar
to, but differs slightly from, the clone responsible for a menin-
gitis outbreak among Hajj pilgrims in 2000 (8,9). Since none
of the patients with W135 meningococci had direct contact
with Hajj pilgrims and Cameroonian W135 strains are slightly
different by PFGE from the W135 clone isolated in Europe
and the United States in 2000, these strains from Cameroon
seem to predate the 2000 Hajj-associated outbreak. A larger
study of the W135 strains isolated in Africa, Europe, and Asia,
from patients with no direct link to the pilgrimage to Mecca
(indigenous strains) would make it possible to identify the
geographic origin of the strain responsible for the Mecca epi-
demic in 2000. Such studies would also make it possible to
elucidate the role of A and C vaccination in the selection of
W135 clones belonging to the ET-37 complex.
We cannot explain with certainty why serogroup A
meningococci has increased in Yaoundé, but the finding
stresses the importance of continuous surveillance. The circu-
lation of W135 strains in Central Africa raises questions about
their epidemic potential and highlights the microbiologic sur-
veillance of meningococcal meningitis. Thus, anti-W135 sero-
grouping antibodies are necessary for all National Reference
Laboratory services. Antigen-detection kits for the diagnosis
of meningitis should also contain anti-W135 antibodies. More-
over, the problem of the availability of a quadrivalent vaccine,
including the W135 antigen, should be resolved. Strengthen-
ing the capacities for epidemiologic and microbiologic surveil-
lance of meningitis in Africa is a prerequisite for prevention
and control of meningococcal epidemics.
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